SECsense Logo

Protalix BioTherapeutics 8-K Report: Key Update on December 23, 2024

$PLX
Form 8-K
Filed on: 2024-12-23
Source
Protalix BioTherapeutics 8-K Report: Key Update on December 23, 2024

Based on the provided XML section of the financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Protalix BioTherapeutics, Inc.
  • CIK Number: 0001006281
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 001-33357
  • Employer Identification Number (EIN): 65-0643773
  • Headquarters Address: 2 University Plaza Suite 100, Hackensack, NJ 07601
  • Phone Number: 201-696-9345
  1. Filing Details:
  • Filing Type: 8-K (Current Report)
  • Filing Date: December 23, 2024
  1. Stock Information:
  • Type of Stock: Common stock
  • Par Value: $0.001
  • Ticker Symbol: PLX
  • Exchange: NYSE American
  1. Reporting Period:
  • Start Date: December 23, 2024
  • End Date: December 23, 2024

Insights:

  • The report is a Current Report (8-K), which typically indicates that the company is announcing significant events or changes that shareholders need to be aware of. The specific nature of these events is not detailed in the provided text.
  • Protalix BioTherapeutics is a publicly traded company listed on the NYSE American under the symbol PLX, indicating it is subject to SEC regulations and reporting requirements.
  • The company’s headquarters in Hackensack, NJ, and its incorporation in Delaware suggest it is positioned to operate within a competitive biotechnology sector.

Conclusion:

This 8-K filing suggests that Protalix BioTherapeutics is reporting an important update or event as of December 23, 2024. Stakeholders should monitor any additional attached documents or subsequent filings to comprehend the full context of this reporting.